Allogene Therapeutics (ALLO) Operating Expenses (2018 - 2026)

Allogene Therapeutics has reported Operating Expenses for 9 years, with the latest figure at $46.1 million in Q1 2026.

• Quarterly Operating Expenses fell 29.3% year-over-year to $46.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $190.2 million (down 29.26% YoY) and the FY2025 annual result came in at $209.3 million, down 23.39% from the prior year.
• Operating Expenses grew to $46.1 million in Q1 2026 per ALLO's latest filing, from $42.4 million in the prior quarter.
• Over five years, Operating Expenses peaked at $99.1 million in Q1 2023 and troughed at $42.4 million in Q4 2025.
• A 5-year average of $70.1 million and a median of $71.4 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses surged 30.4% in 2022, then sank 37.44% in 2025.
• Over 5 years, Operating Expenses stood at $96.4 million in 2022, then retreated by 11.71% to $85.1 million in 2023, then fell by 28.94% to $60.5 million in 2024, then retreated by 29.9% to $42.4 million in 2025, then rose by 8.7% to $46.1 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $46.1 million, $42.4 million, and $44.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.